Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Tumor neoantigenicity metric improves prediction of response to immunotherapy

Key clinical point: Compared with existing metrics, the Cauchy-Schwarz index of neoantigens (CSiN) score may be better at predicting response to immunotherapy among patients with immunogenic cancer.

Major finding: There was a significant positive association between higher CSiN scores and better response among melanoma patients who received anti–CTLA-4 therapy (P = .009), patients with clear cell renal cell carcinoma treated with anti-PD-1/PD-L1 therapy (P = .036), and patients with non–small cell lung cancer treated with checkpoint inhibitors (P = .015).

Study details: A retrospective study of 2,479 cancer patients.

Disclosures: The study was funded by the National Institutes of Health, the Cancer Prevention Research Institute of Texas, and the American Cancer Society. The investigators reported no conflicts of interest.


Lu et al. Sci Immunol. 2020 Feb 21. doi: 10.1126/sciimmunol.aaz3199.